LDS/Medical Tests/Lipoprotein Profile (Lipoprotein Particle), High Resolution Fractionation and Quantitation

Lipoprotein Profile (Lipoprotein Particle), High Resolution Fractionation and Quantitation

The Lipoprotein profile that comprises LDL, HDL, VLDL, LP(a) or Lipoprotein (a), APO A-1, APO B, APO C, and APO E is used to uncover the causes of heart disease, differentiate causes of diabetes, cholesterol disorders, and even Alzheimer’s and Tangier’s disease.

Lipoproteins are differentiated by ultracentrifugation based on their density into chylomicrons, such as very low density lipoproteins (VLDL), low density lipoproteins (LDL), and high density lipoproteins (HDL). Lipoproteins may also be separated by electrophoresis into the beta (LDL), prebeta (VLDL), and alpha (HDL) lipoproteins. Along with the lipoprotein profile and lipid panel other considerations should be considered when making diagnosis; these considerations include family history of heart disease, age, sex, and other risk factors.

Low Density Lipoprotein (LDL)

Low LDL is seen in abetalipoproteinemia and in familial hypoproteinemia. However, most patients with low LDL have the latter disorder, familial hypobetalipoproteinemia. These patients have a truncated apo-B protein. A third disorder with a low LDL is Anderson's disease, a disorder of unknown etiology. Increased levels indicate increased risk of heart disease and stroke, as well as other related cardiovascular diseases.

High Density Lipoprotein (HDL)

Decreased levels of high density lipoprotein (HDL) in plasma indicate increased risk coronary heart disease. Low levels of HDL (<40mg/dL) are associated with increased myocardial risk and increased risk of coronary angioplasty restenosis. HDL can be fractionated into two measurable subfractions, HDL2 and HDL3. Diet and exercise may increase the number of HDL particles.

VLDL and Lipoprotein

Lipoproteins are transporters of cholesterol and lipids. Lipoprotein particles consisting of LDL particles bound to lipoproteins such as apolipoprotein (apo[a]) apo B-100, and ApoE. Increased levels indicate high risk of cardiovascular and heart disease.

Apolipoproteins

Apolipoproteins are the protein constituents of the lipoproteins that are the transporters of cholesterol and other important cell molecules. The Apolipoprotein Assessment consists of the Apolipoprotein A1 (an apoprotein of the High Density Lipoproteins-HDL) and Apolipoprotein B (major protein component of Low Density Lipoprotein-LDL). Apolipoproteins are produced in the liver and intestine. There are at least nine types of apolipoproteins including apo A-I, apo B, and apo E. Apolipoprotein A (apo A) is the major polypeptide component of HDL. Apo A has two major forms: apo A-I which constitutes 75% of the apo A in HDL, and apo A-II which constitutes the remainder of apo A of the total HDL protein. Low levels of apo A are associated with the increased risk of coronary artery disease (CAD)

  • Used in conjunction with a lipid panel to assist in diagnosis of coronary heart diseases such as potential for heart attack and stroke
  • Determine source of abnormal lipid metabolism
  • Assist in diagnosis of diabetes mellitus, Alzheimer’s and Tangier’s disease
  • Assist in diagnosis of cholesterol disorders

Increased in:

  • Heart disease
  • Stroke
  • Coronary artery disease
  • Nephrotic Syndrome
  • Chronic Renal Failure
  • Steroid Immunosuppressive Therapy
  • Cholestasis; Intra or Extrahepatic
  • Acute Pancreatitis
  • Diabetes Mellitus
  • Type I Glycogen Storage Disease
  • Hypothyroidism
  • Gout
  • Pregnancy
  • Oral Contraceptives
  • Acute Alcoholism
  • e4 version of APO E; increase is related to Alzheimer’s disease
  • APO A-1 increased in Tangier’s disease
  • LDL increased Hypothyroidism and Nephrotic syndrome

Decreased in:

  • abetalipoproteinemia and in familial hypoproteinemia (low LDL)
  • Anderson's disease (low LDL)
  • Risk of coronary heart disease (low HDL)
  • Increase myocardial risk (low HDL)
  • Cigarette smoking (low HDL)
  • Obesity (low HDL)
  • Steroid taking (low HDL)
Element Optimal Borderline High risk
LDL-C <100mg/dL 130-159mg/dL 160+mg/dL
HDL-C >60mg/dL 35-45mg/dL <35mg/dL
VLDL-C
Lipoprotein (a) <20 mg/dL 20-30mg/dL >30mg/dL
Apolipoprotein A-1 (men) 110-205mg/dL    
Apolipoprotein B-100 (men) 55-140mg/dL    
Apolipoprotein E 20-60mg/L    
RIA (Radioimmunoassay), ELISA (Enzyme-Linked ImmunoSorbent Assay), RID (Radical ImmunoDiffusion), Enzymatic, Colorimetric methods to separate LDL, HDL, and VLDL, nuclear magnetic resonance spectroscopy.

Serum (SST), red top (preferred). 

Stability

  • Ambient: 3-5 days
  • Refrigerated: 5-7 days
  • Frozen: 30 days
Lipid panel, Nuclear magnetic resonance (NMR), Gradient gel electrophoresis (GGE) and Vertical Auto-Profile (VAP), Apolipoprotein A-I, Apolipoprotein B-100, C-reactive protein (CRP), Homocysteine, Comprehensive metabolic panel, CBC.
2-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Curr Atheroscler Rep. 2011 Dec 2. [PMID: 22135161]
  • Adv Clin Chem. 2008;46:295-317. [PMID: 19004193]
  • Arch Pathol Lab Med. 1989 Oct;113(10):1101-10. [PMID: 2679486]
  • Engl J Med. 1999; 341:498-511. [PMID: 10441607]
  • JAMA. 1985; 253:2080-6. [PMID: 3974099]
  • JAMA. 2001; 285:2486-97. [PMID: 11368702]
  • J Am Coll Cardiol. 1993; 22:933-40. [PMID: 7689082]
  • N Engl J Med. 1991; 325:373-81. [PMID: 2062328]
  • Lexi-Comp’s Laboratory Test Handbook 3rd Edition; 202-205.
  • Marks V, Cantor T, Mesko D, Pullmann R, Nosalova G. Differential Diagnosis by Laboratory Medicine. Springer (2003).
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login